Rhenman & Partners Asset Management AB Has $20.91 Million Position in CVS Health Corporation $CVS

Key Points

• Rhenman & Partners cut its CVS stake by 6.1% in Q3 to 277,362 shares valued at $20.91 million, making CVS its ninth-largest holding.
• Wall Street is mostly bullish — the consensus rating is "Moderate Buy" with a $94.91 target, and analysts have raised price targets after CVS beat quarterly EPS ($1.09 vs. $1.00) and issued FY2026 guidance of 5.94–6.14 EPS.
• CVS launched Health100, an AI-native platform built with Google Cloud that could drive long-term revenue and margin recovery, but faces regulatory risk in Tennessee that could force the closure of 134 pharmacies.

Rhenman & Partners Asset Management AB reduced its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 6.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,362 shares of the pharmacy operator's stock after selling 18,000 shares during the quarter. CVS Health accounts for approximately 2.3% of Rhenman & Partners Asset Management AB's holdings, making the stock its 9th biggest position. Rhenman & Partners Asset Management AB's holdings in CVS Health were worth $20,910,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ameriflex Group Inc. raised its position in shares of CVS Health by 361.2% during the third quarter. Ameriflex Group Inc. now owns 2,624 shares of the pharmacy operator's stock valued at $198,000 after buying an additional 2,055 shares during the last quarter. Blair William & Co. IL increased its stake in CVS Health by 2.2% during the third quarter. Blair William & Co. IL now owns 63,409 shares of the pharmacy operator's stock valued at $4,780,000 after acquiring an additional 1,357 shares during the period. Modern Wealth Management LLC raised its holdings in CVS Health by 12.9% in the 3rd quarter. Modern Wealth Management LLC now owns 3,961 shares of the pharmacy operator's stock valued at $299,000 after acquiring an additional 452 shares in the last quarter. Neo Ivy Capital Management lifted its position in shares of CVS Health by 747.4% in the 3rd quarter. Neo Ivy Capital Management now owns 10,626 shares of the pharmacy operator's stock worth $801,000 after acquiring an additional 9,372 shares during the period. Finally, Perennial Investment Advisors LLC acquired a new stake in shares of CVS Health during the 3rd quarter worth approximately $208,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on CVS shares. Royal Bank Of Canada restated an "outperform" rating on shares of CVS Health in a research note on Thursday, December 4th. Mizuho lifted their price target on shares of CVS Health from $88.00 to $95.00 and gave the stock an "outperform" rating in a research note on Wednesday, December 10th. JPMorgan Chase & Co. increased their price objective on shares of CVS Health from $93.00 to $101.00 and gave the company an "overweight" rating in a research note on Wednesday, December 17th. Morgan Stanley lifted their target price on shares of CVS Health from $89.00 to $93.00 and gave the company an "overweight" rating in a research report on Wednesday, December 10th. Finally, UBS Group reissued an "outperform" rating on shares of CVS Health in a research report on Wednesday, December 10th. Nineteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $94.91.

CVS Health Stock Down 1.0%

Shares of NYSE:CVS opened at $77.91 on Friday. The company's fifty day moving average is $78.49 and its 200-day moving average is $77.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $85.15. The company has a market capitalization of $99.12 billion, a PE ratio of 56.46, a P/E/G ratio of 0.81 and a beta of 0.49.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.09. The business had revenue of $105.69 billion during the quarter, compared to analysts' expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm's revenue for the quarter was up 8.2% on a year-over-year basis. During the same quarter last year, the company posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.4%. CVS Health's payout ratio is currently 192.75%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS launched Health100, a new AI-native health‑tech subsidiary and consumer engagement platform built with Google Cloud. Management says the platform will unify data across payers, providers and pharmacies to drive personalized engagement and better outcomes — a potential long‑term revenue and margin lever if adoption scales. CVS taps Google Cloud to roll out AI-powered health platform
• Positive Sentiment: Broad media and trade coverage highlights the Google Cloud tie‑up and Health100 rollout, increasing visibility for CVS as a tech-enabled healthcare integrator — this can support multiple revenue streams (retail, PBM, value-based care) over time. CVS Health And Google Launch AI Business To ‘Personalize Healthcare'
• Positive Sentiment: Analyst and long‑term bulls point to margin recovery and FY2026 guidance (CVS set EPS guidance ~5.94–6.14) plus a recent quarterly beat — supporting the thesis that Medicare Advantage margin improvement and Health100 monetization could drive sizable upside over 12–24 months. CVS Health: Stop Catastrophizing, Start Believing - Here's Why
• Neutral Sentiment: Market commentary questions whether recent gains already price in recovery — some pieces analyze valuation and one‑year returns, useful for timing but not a direct catalyst. Is CVS Health (CVS) Still Attractive After A 27% One Year Share Price Gain
• Negative Sentiment: Regulatory risk in Tennessee: a proposed bill would bar companies from owning both retail pharmacies and PBMs, and CVS warned it could close all 134 locations in the state if the law passes — an example of state‑level regulatory risks that could hit revenue, footprint and investor sentiment. CVS warns bill would force shutdown of 134 pharmacies in this state
• Negative Sentiment: Wolfe Research trimmed its price target on CVS, a modest negative for near‑term sentiment even though the firm remains focused on longer‑term fundamentals. Wolfe Research Cuts CVS Health NYSE: CVS Price Target to $97.00

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.